Moxamar (Moxonidine)

Moxonidine selectively activates imidazoline I1 receptors in the brainstem, which diminishes sympathetic outflow. This leads to reduced peripheral vascular resistance and a subsequent decrease in arterial blood pressure.

The appropriate dose of Moxamar is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of moxonidine in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Moxamar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Moxamar belongs to the imidazoline receptor agonist class, which lowers blood pressure by reducing sympathetic activity. Unlike ACE inhibitors or beta‑blockers, it targets central pathways, offering an alternative mechanism that may be useful when patients experience side effects or inadequate control with other agents.

Moxamar should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain its stability and potency.

Moxamar is taken orally, usually with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe hypotension, bradycardia, allergic reactions such as rash or swelling, and rare liver enzyme elevations. Patients should seek immediate medical attention if they experience symptoms like fainting, rapid heartbeat, difficulty breathing, or unusual skin changes.

Moxamar is contraindicated in patients with known hypersensitivity to moxonidine or any excipients in the formulation. Caution is advised for individuals with severe renal or hepatic impairment, and it should be avoided in patients taking other central antihypertensive agents without medical supervision.